Reduced relapse rates

Down arrow

50%

reduction in annualized
relapse rate vs placebo1*

Other endpoint. Results are descriptive. NUCALA
vs placebo, annualized relapse rate 1.14 vs 2.27;
rate ratio: 0.50, 95% CI: 0.36, 0.70. 

Other endpoint. Results are descriptive.
NUCALA vs placebo, annualized relapse rate 1.14 vs 2.27; rate ratio: 0.50, 95% CI: 0.36, 0.70.   

Patients on NUCALA had significantly longer time to first relapse1*

Secondary endpoint: Time to first relapse

Graph displaying patients on NUCALA had significantly longer time to first relapse
Graph displaying patients on NUCALA had significantly longer time to first relapse

NUCALA vs placebo, HR: 0.32, 95% CI: 0.21, 0.50; P<0.001

Relapse was defined as a worsening related to vasculitis, asthma, or sinonasal symptoms requiring an increase in dose of corticosteroids, increase in dose or addition of immunosuppressive therapy, or hospitalization.1

NUCALA and placebo were administered in addition to standard of care (SOC).

I bars at Weeks 16, 32, and 52 indicate 95% confidence intervals.

Reduction in relapse rates by type

Subgroup analysis: The incidence and number of relapses by type were lower with NUCALA vs placebo2* 

Subgroups by relapse type were not large enough to determine statistical significance; therefore, results are descriptive only.

Total number of relapses by type: NUCALA (n=68) vs placebo (n=68)*

Relapses icon

All relapses

Number of relapses

NUCALA 88 (n=38) 56%
vs placebo 154 (n=56) 82%*

NUCALA 88 (n=38) 56% vs placebo 154 (n=56) 82%*

Down arrow

43%

reduction

vs placebo
Vasculitis icon

Any vasculitis

Number of relapses

NUCALA 45 (n=29) 43%
vs placebo 83 (n=44) 65%*

NUCALA 45 (n=29) 43% vs placebo 83 (n=44) 65%*

Down arrow

46%

reduction

vs placebo
Sinonasal icon

Any sinonasal

Number of relapses

NUCALA 46 (n=24) 35%
vs placebo 85 (n=35) 51%*

NUCALA 46 (n=24) 35% vs placebo 85 (n=35) 51%*

Down arrow

46%

reduction

vs placebo
Lung icon

Any asthma

Number of relapses

NUCALA 66 (n=25) 37%
vs placebo 112 (n=41) 60%*

NUCALA 66 (n=25) 37% vs placebo 112 (n=41) 60%*

Down arrow

41%

reduction

vs placebo

NUCALA and placebo were administered in addition to standard of care (SOC). SOC was defined as OCS +/– immunosuppressants. After Week 4, OCS (prednisolone or prednisone) dose could be tapered per physician judgment or a suggested protocol.

Relapse types2

Vasculitis icon

Vasculitis
Relapse with active vasculitis (BVAS>0)

Sinonasal icon

Sinonasal
Relapse with active nasal and/or sinus disease and worsening in ≥1 sinonasal symptom questions

Lung icon

Asthma
Relapse with active asthma symptoms and/or signs and worsening in ACQ-6 score

BVAS is a standardized, validated measure of vasculitis. Scores can range from 0 to 63, with higher scores meaning more active disease.3,4 

ACQ-6=Asthma Control Questionnaire-6; BVAS=Birmingham Vasculitis Activity Score; CI=confidence interval; HR=hazard ratio; OCS=oral corticosteroid; SOC=standard of care.